Browsing Tag
Gene therapy company
10 posts
Eli Lilly completes $1.04bn acquisition of Prevail Therapeutics to expand gene therapy program
Eli Lilly and Company has officially finalized its acquisition of Prevail Therapeutics in a deal valued at up…
Eli Lilly to acquire Prevail Therapeutics for $1.04bn, expanding gene therapy pipeline
Eli Lilly and Company has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a…
Janssen acquires HMR59 from Hemera for geographic atrophy treatment
Janssen Pharmaceuticals has secured the rights to an innovative gene therapy, HMR59, for the treatment of geographic atrophy,…
Gene therapy company 4D Molecular Therapeutics raises $70m in Series C round
California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector…
Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy
Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US…
Astellas Pharma to acquire US gene therapy company Audentes Therapeutics
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes…
Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy
Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to…
Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma
Cellectis said that it has dosed the first patient in a phase 1 study – the MELANI-01 clinical…
Avrobio gets FDA orphan status for AVR-RD-02 in Gaucher disease
US gene therapy company Avrobio has secured orphan-drug designation for AVR-RD-02, its investigational gene therapy, for the treatment…
4D Molecular Therapeutics secures $90m in Series B to advance gene therapy innovations
California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has…